Showing results (421-430 of 524) with videos related to
Sort By:
Pageof 53
Diabetes, Obesity & Metabolism|October 4, 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist usePeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.Journal of the American Society of Hypertension : JASH|July 26, 2016
Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensivesJuan A Divisón-Garrote, José R Banegas, Juan J De la Cruz, et al.American Heart Journal|September 18, 2012
Implications of geographical variation on clinical outcomes of cardiovascular trialsRobert J Mentz, Juan-Carlos Kaski, Gheorghe-Andrei Dan, et al.European Heart Journal|May 25, 2011
Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibitionAgostino Virdis, Rocchina Colucci, Mario Fritsch Neves, et al.Translational Research : the Journal of Laboratory and Clinical Medicine|August 2, 2016
Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progressionLaura Gonzalez-Calero, Marta Martin-Lorenzo, Paula J Martínez, et al.Kidney International|November 11, 2022
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetesGeorge L Bakris, Luis M Ruilope, Stefan D Anker, et al.Journal of the American Medical Directors Association|March 2, 2017
Magnitude of Hypotension Based on Office and Ambulatory Blood Pressure Monitoring: Results From a Cohort of 5066 Treated Hypertensive Patients Aged 80 Years and OlderJuan A Divisón-Garrote, Luis M Ruilope, Alejandro de la Sierra, et al.The American Journal of Medicine|November 26, 2008
Gender differences in office and ambulatory control of hypertensionJosé R Banegas, Julián Segura, Alejandro de la Sierra, et al.BMJ Open|March 20, 2024
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trialsShweta Bansal, Maria E F Canziani, Rita Birne, et al.British Journal of Pharmacology|August 25, 2020
Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca2+ handlingJosé Alberto Navarro-García, Angélica Rueda, Tatiana Romero-García, et al.Pageof 53